We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.

Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.

We believe Pfizer and BioNTech's vaccine is set up for emergency use this year, followed by full approval in 2021 pending supportive final data.

And what we expect to see moving forward.